PROVIDER OUICK POINTS PROVIDER INFORMATION



March 24, 2021

Cellular and Gene Therapy Product Reimbursement Policy Update

Blue Cross and Blue Shield of Minnesota and Blue Plus will be updating the Cellular and Gene Therapy Product Reimbursement Policy to reflect quarterly coding changes announced by the Centers for Medicare & Medicaid Services (CMS) as it updates its Healthcare Common Procedural Coding System (HCPCS) Level II codes that will be going into effect on April 1, 2021.

Products Impacted

This change only applies to commercial lines of business.

Coding requirements reminder

This is not a change in medical policy, member benefits, or prior authorization (PA) requirements for cellular and gene therapy products, but a HCPCS coding update. All coding and reimbursements are subject to changes, updates, or other requirements of coding rules and guidelines to comply with federal HIPAA rules. In the case of medical code sets (e.g. HCPCS, CPT[®], ICD), only valid codes for the date of service may be submitted or accepted. To access the reimbursement policy:

- Go to providers.bluecrossmn.com
- Under Tools & Resources, select "Reimbursement Policies"
- Locate "Cellular and Gene Therapy Products"

Questions?

If you have questions, please contact provider services at (651) 662-5200 or 1-800-262-0820.

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association

Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association. L264R03 (12/13)

Distribution: bluecrossmn.com/providers/forms-and-publications